pharmaphorum January 14, 2022
Japanese pharma group Otsuka has led a $10 million first-round financing of GrayMatters Health, an Israeli company developing a digital health approach to the management of mental illness.
Otsuka Medical Devices is also taking some rights to GrayMatters’ platform – called Prism – in Japan and some other Asian countries in connection with the financing, which was supported by Joy Ventures, J-Ventures, J-Impact, and existing backers Marius Nacht and Joyance Ventures.
Described as a digital self-neuromodulation therapy, the Prism platform is initially being developed for people suffering from post-traumatic stress disorders (PTSD).
GrayMatters’ approach relies on using functional magnetic resonance imaging (fMRI) and electroencephalograph (EEG) analyses in tandem, with machine learning applied to identify a “fingerprint” of electrical activity in...
Today's Sponsors
Today's Sponsor